For Node-Positive Breast Cancer, EC-T Remains Standard Adjuvant Regimen

Share this content:
In node-positive early breast cancer, invasive disease-free but not overall survival was significantly superior with adjuvant standard regimen.
In node-positive early breast cancer, invasive disease-free but not overall survival was significantly superior with adjuvant standard regimen.

In patients with node-positive early breast cancer, invasive disease-free survival, but not overall survival, was significantly superior for those who received the adjuvant standard schedule epirubicin plus cyclophosphamide followed by docetaxel (EC-T) than for those who received the experimental epirubicin plus docetaxel followed by capecitabine (ET-X) regimen, a new study published online ahead of print in the Journal of Clinical Oncology has shown.1

Because capecitabine is an active drug in metastatic breast cancer, researchers sought to evaluate the integration of capecitabine into an adjuvant regimen of epirubicin and docetaxel for patients with node-positive early breast cancer.

“We tried to see if introducing capecitabine in the adjuvant therapy of breast cancer could be of interest,” said lead author Miguel Martin, MD, PhD, of the Instituto de Investigación Sanitaria Gregorio Marañón at Universidad Complutense in Spain, in an interview with Cancer Therapy Advisor.

RELATED: Metformin Use May Improve Survival in Patients With Breast Cancer, Diabetes

For the study, researchers enrolled 1,384 patients who had undergone surgery for T1-3/N1-3 breast cancer. Participants were randomly assigned to receive epirubicin 90 mg/m2 intravenously plus cyclophosphamide 600 mg/m2 intravenously for 4 cycles, followed by docetaxel 100 mg/m2 intravenously for 4 cycles, or epirubicin 90 mg/m2 intravenously plus docetaxel 75 mg/m2 intravenously for 4 cycles, followed by capecitabine 1,250 mg/m2 orally twice daily on days 1 to 14 for 4 cycles. Both regimens were administered in 3-week cycles.

Patients with hormone receptor-positive tumors then received tamoxifen 20 mg once daily or an aromatase inhibitor for 5 years, or received the aromatase inhibitor sequentially with tamoxifen.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs